Biotronik hybrid stent shows efficacy in clinical study

Biotronik has announced that an innovative new hybrid drug-eluting stent (DES) system it has developed has demonstrated its effectiveness in a clinical study.

The Orsiro Hybrid stent is the first device of its kind to feature both passive and active components, with its mix of Probio and Biolute coatings enabling drug delivery efficacy while minimising interaction with surrounding tissue.

It was trialled in a first-in-man study called Bioflow-I, a 30-patient research programme which showed that the device can help to protect against major adverse cardiac events and in-stent late lumen loss after nine months.

Biotronik is now initiating a pan-European study, Bioflow-II, which will involve 440 patients, while enrolment for the global Bioflow-III trial is also currently underway.

Alain Aimonetti, vice-president of sales and marketing for Biotronik's vascular intervention division, said: "The exciting addition of the Orsiro Hybrid DES allows us to offer the world's most advanced product portfolio for vascular intervention and paves the way for the drug-eluting absorbable scaffold we are developing."

Earlier this month, the company highlighted its recent business development at an industry event in the US, expressing satisfaction with its above-the-market growth rate over the last few years.